Description
The Supreme Court’s decision in Purdue Pharma has significant implications for cross-border insolvency practice under chapter 15. This panel will examine how the ruling is reshaping the legal landscape for foreign main proceedings, recognition standards, and especially the use of nonconsensual third-party releases. The panelists also will explore emerging questions around comity, enforcement of foreign judgments, and the limits of U.S. bankruptcy courts’ authority in cross-border cases.
Speakers
Conference